Characterization and miRNA Profiling of Extracellular Vesicles from Human Osteoarthritic Subchondral Bone Multipotential Stromal Cells (MSCs) by Sanjurjo-Rodríguez, C et al.
Research Article
Characterization and miRNA Profiling of Extracellular
Vesicles from Human Osteoarthritic Subchondral Bone
Multipotential Stromal Cells (MSCs)
Clara Sanjurjo-Rodríguez ,1,2,3 Rachel E. Crossland ,1 Monica Reis ,1,4
Hemant Pandit ,2,5 Xiao-nong Wang ,1 and Elena Jones 2
1Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, NE2 4HH, UK
2Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds LS9 7TF, UK
3Cell Therapy and Regenerative Medicine Group, Physiotherapy, Medicine and Biomedical Sciences Department,
Universidade da Coruña, A Coruña 15006, Spain
4Department of Pediatrics, Harvard Medical School, Boston, MA 02115, USA
5Leeds Teaching Hospitals NHS Trust, Leeds LS7 4SA, UK
Correspondence should be addressed to Xiao-nong Wang; x.n.wang@newcastle.ac.uk and Elena Jones; e.jones@leeds.ac.uk
Received 20 April 2021; Revised 26 July 2021; Accepted 19 August 2021; Published 9 October 2021
Academic Editor: Quanyi Guo
Copyright © 2021 Clara Sanjurjo-Rodríguez et al. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work
is properly cited.
Osteoarthritis (OA) is a heterogeneous disease in which the cross-talk between the cells from different tissues within the joint is
affected as the disease progresses. Extracellular vesicles (EVs) are known to have a crucial role in cell-cell communication by
means of cargo transfer. Subchondral bone (SB) resident cells and its microenvironment are increasingly recognised to have a
major role in OA pathogenesis. The aim of this study was to investigate the EV production from OA SB mesenchymal stromal
cells (MSCs) and their possible influence on OA chondrocytes. Small EVs were isolated from OA-MSCs, characterized and
cocultured with chondrocytes for viability and gene expression analysis, and compared to small EVs from MSCs of healthy
donors (H-EVs). OA-EVs enhanced viability of chondrocytes and the expression of chondrogenesis-related genes, although the
effect was marginally lower compared to that of the H-EVs. miRNA profiling followed by unsupervised hierarchical clustering
analysis revealed distinct microRNA sets in OA-EVs as compared to their parental MSCs or H-EVs. Pathway analysis of OA-
EV miRNAs showed the enrichment of miRNAs implicated in chondrogenesis, stem cells, or other pathways related to
cartilage and OA. In conclusion, OA SB MSCs were capable of producing EVs that could support chondrocyte viability and
chondrogenic gene expression and contained microRNAs implicated in chondrogenesis support. These EVs could therefore
mediate the cross-talk between the SB and cartilage in OA potentially modulating chondrocyte viability and endogenous
cartilage regeneration.
1. Introduction
Osteoarthritis (OA) is a heterogeneous disease that affects
synovial joints, which starts from injury or as a molecular
alteration and results in structural changes, such as loss of
cartilage, bone sclerosis or osteophyte formation, pain, and
other clinical symptoms [1]. OA is one of the most prevalent
joint diseases and frequently causes disability, with high inci-
dence worldwide due to population aging [2–4].
Early OA changes in articular cartilage include regional
proteoglycan loss, chondrocyte clustering, collagen disorga-
nization, and tissue fibrillation [5]. While the catabolic/ana-
bolic imbalance in bone is associated to overloading
microdamages, in cartilage it seems to be associated with
persistent, low-grade inflammation [6]. It begins in the
synovial tissue where it is characterized by cytokine release
and immune cell infiltration and is commonly associated
with pain in OA [7, 8]. With OA progression, subchondral
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bone (SB) gains more influence on OA chondrocytes as
osteochondral junction becomes more porous [5, 6, 9–13].
Bone-targeting treatments have a positive effect on OA
chondrocytes [6] while cocultures of OA subchondral bone
osteoblasts [10] or osteoclasts [14] with OA chondrocytes
have a negative effect on chondrocytes’ viability or anabolic
activity. The bone-cartilage crosstalk is therefore emerging
as a novel therapeutic target for OA [13, 15].
In OA, different types of SB cells enter normally the non-
vascular calcified cartilage through the cracks and fissures or
along the newly formed vessels, all contributing to cartilage
destruction “from below” [12, 16–18]. These SB cells include
osteo/chondroclasts that dissolve the calcified cartilage
matrix [18, 19], neurons that exacerbate joint pain [13, 20,
21], and multipotential stromal cells (MSCs) that may be
involved in both, cartilage formation and cartilage degrada-
tion [12, 18]. Besides the cells themselves, SB-cartilage com-
munication in OA may be mediated via soluble proteins
[22], for example, VEGF or IL6, which are increased in dam-
aged SB areas in OA [23], and or via extracellular vesicles
(EVs); the influence of which on OA chondrocyte homeosta-
sis remains poorly understood [24].
EVs are nonreplicative bilipid-layered particles that are
released naturally from most of the cells, carrying peptides,
miRNAs, lipids, and other molecules in their cargo, which
can be transmitted to other cells. They can be broadly subca-
tegorised based on their biogenesis, size, and markers into
exosomes, microvesicles, and apoptotic bodies [25–27].
EVs have a crucial role in cell-to-cell communication, allow-
ing the cargo transfer through endocytic internalization or
direct fusion to provoke a biological response [28–31].
Recently, studies of EVs in joint diseases and their therapeu-
tic use started to rise [24, 32–35], but these studies are pri-
marily focused on EVs derived from osteoarthritic synovial
fluid rather than SB [36, 37].
The aim of this study was to investigate EV production
from SB MSCs, the cells previously shown to contribute to
disease pathogenesis in OA [18, 38, 39]. We hypothesised
that SB MSC-EVs may have an influence on OA chondro-
cytes’ viability and their anabolic gene expression and that
they contain specific sets of miRNAs that are different from
their parental MSCs.
2. Materials and Methods
2.1. Patients and Cells. Ethical approval for cartilage and
MSC osteoarthritic sample collection was obtained from
the NRES Committees Yorkshire & The Humber—South
Yorkshire (14/YH/0087) and NRES Committees North
East—Newcastle & North Tyneside 1 (14/NE/1212). From
this collection, 11 cartilage samples (6 females and 5 males
with median age 74 years, range 55–83) and 5 subchondral
bone samples (3 females and 2 males with median age 73
years, range 64–83) were collected from total knee
arthroplasty.
Healthy MSC collection was obtained from surplus mate-
rial remaining in 10 bone marrow-processing bags used for
hematopoietic stem cell transplantation (NRES Committee
North East—Newcastle & North Tyneside 2, 14/NE/1136).
Patients were 7 males and 3 females with the median age of
14 years (range 4–44).
2.2. Isolation and Culture of OA Chondrocytes. Articular car-
tilage was harvested from tibiofemoral surfaces, and chon-
drocytes were isolated as previously described [18]. Briefly,
the cartilage was harvested and minced using a scalpel and
digested with collagenase overnight. Chondrocytes were
expanded in a high-glucose Dulbecco’s Modified Eagle
Medium (DMEM; MilliporeSigma, USA) supplemented
with glutamine, 10% fetal bovine serum (FBS; ThermoFisher
Scientific, USA), and 1% penicillin/streptomycin (P/S; Milli-
poreSigma, USA). Media were changed twice a week, and
subculture was performed when chondrocytes reached 80%
confluence, and passaged to passage 2 (p2).
2.3. Isolation and Culture of MSCs. Osteoarthritic MSCs
were obtained from the subchondral bone of medial femoral
condyles after removal of cartilage, as previously described
[18]. Medial condyles were chosen as they commonly dis-
play a more prominent OA phenotype compared to lateral
condyles [18, 40]. Bone was weighted and mechanically
minced into small fragments with a rongeur and digested
with collagenase, as previously described [18]. MSC cultures
were established in StemMACs™ MSC expansion media
(Miltenyi Biotec, Germany) then transferred to DMEM sup-
plemented with 5% human platelet lysate (PL; PLTMax,
MilliporeSigma), 100 IU/ml penicillin, 100ug/ml streptomy-
cin, 2,500 IU/ml heparin and 2mML-glutamine (all from
MilliporeSigma) (5%PL/DMEM).
Healthy control MSCs were cultured from surplus cells
(wash-outs) of hematopoietic stem cell transplantation bags,
as previously described [41]. Briefly, bone marrow mononu-
clear cells (MNCs) were isolated by density gradient centri-
fugation and cultured in 5%PL/DMEM.
Both types of MSCs were previously characterized [18,
41] (Supplementary Figures 1 and 2) according to the
criteria set by the International Society of Cellular Therapy
(ISCT) [42] and expanded in 5%PL/DMEM to passage 3
before changing the media to EV-depleted 5%PL/DMEM,
for EV isolation. EV-depleted MSC media were prepared
by 18-hour ultracentrifugation of 10%PL/DMEM at
100,000 × g followed by 1 : 1 dilution in DMEM.
2.4. EV Isolation from OA and Control MSCs. EVs were iso-
lated from both osteoarthritic (OA-EVs) and control healthy
(H-EVs) p3 MSCs, as previously described [41]. In brief,
when the cells reached 50% confluence, they were washed
twice with phosphate buffered saline (PBS, MilliporeSigma)
and cultured in a 5%PL/DMEM-EV-depleted medium, for
a further duration of 48 hours prior to harvesting the condi-
tioned media and MSC-EV isolation. In addition to collect-
ing the conditioned medium, the number of MSCs in the
flask was counted and an aliquot of cells was frozen as pellets
in a QIAzol lysis reagent (Qiagen, Germany) for RNA isola-
tion. To obtain MSC-EVs, the conditioned medium was cen-
trifuged at 400 × g for 5min, 2,000 × g for 20min at 4°C,
then transferred to ultracentrifuge tubes (Beckman Coulter,
USA) and centrifuged again sequentially at 10,000 × g for
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45min and at 100,000 × g for 90min at 4°C, using a 45Ti
rotor (Beckman Coulter) in a Optima XE-90 ultracentrifuge
(Beckman Coulter). The MSC-EVs pellet was washed in PBS
then resuspended in approximately 200-300μl sterile PBS
and stored at −80°C.
2.5. MSC-EV Characterization. MSC-EV characterization
was performed by electron microscopy (TEM), flow cytom-
etry, and nanoparticle tracking analysis (NTA) [41].
For TEM, 5μl of MSC-EVs was adsorbed for 30 s onto a
carbon-coated, glow-discharged grid. Excess liquid was
removed and samples were stained with 1% uranyl acetate
(Agar Scientific, UK). Excess uranyl acetate solution was
removed, and the MSC-EV-loaded grids were dried then
examined using a Hitachi HT7800 transmission electron
microscope. Digital images were collected using an Emsis
Xarosa camera with Radius software.
EV surface markers CD63, CD9, and CD81 were ana-
lyzed by flow cytometry following coating of 4μm aldehy-
de/sulfate latex beads (ThermoFisher Scientific) with 10μl
of MSC-EVs suspension. The reaction was stopped by incu-
bation with 1M glycine (MilliporeSigma), and the MSC-EV-
bead complex was washed twice with PBS then incubated
with mouse anti-human PE CD63 (clone H5C6),
PerCPCy5.5 CD9 (clone M-L13), and APC CD81 (clone
JS-81) antibodies or corresponding isotype controls (all from
BD Biosciences, USA). Following further washes, cells were
resuspended in particle-free PBS (ThermoFisher Scientific)
and data was acquired using a BD FACS Canto II cytometer
(BD Biosciences) and analyzed with FlowJo 10.0 software
(Tree Star Inc., USA).
For NTA, MSC-EV pellets were diluted with sterile
particle-free PBS and analyzed using Nanosight LM10 (Mal-
vern Panalytical Ltd, UK), as described by the manufac-
turer’s protocol. Three 60 s measurements of the particle
size and concentration were measured for each sample.
The acquired data was processed using NTA 2.3 software
(Malvern Panalytical Ltd).
2.6. ATP-Based Viability Assessment of Chondrocytes
following Coculture with MSC-EVs. The CellTiter-Glo 2.0
Luminiscent Cell Viability Assay (Promega, UK) measures
total ATP levels produced by metabolically active cells. For
this assay, EV-depleted chondrocyte media was first pre-
pared by 18-hour ultracentrifugation of DMEM/Nutrient
Mixture F-12 (DMEM:F12, ThermoFisher Scientific) con-
taining 10% FBS (DMEM:F12/10%FBS) at 100,000 x g and
optimal conditions (5 × 103 chondrocytes/well, 24-hour
treatment duration) established by seeding different cell con-
centrations and determining the ATP levels.
To determine the effect of MSC-EVs (both OA- and H-
EVs) on chondrocytes’ ATP levels, EVs from 6 × 104 MSCs
were added into 300μl of EV-depleted DMEM:F12/10%FBS
containing 1:5 × 104 chondrocytes (MSC to chondrocyte
ratio of 4 : 1 [43], and 100μl of the mix (containing 5 × 103
chondrocytes) was seeded in triplicate wells of the same 96-
well Nunclon delta plates. As a control, 5 × 103 chondrocytes
without MSC-EVs were plated in triplicate wells containing
100μl of the same EV-depleted DMEM:F12/10%FBS media.
A second dose of EVs from 6 × 104 MSCs was added on day
3, and luminescence measurements were performed on day
5. For this, 100μl of equilibrated CellTiter-Glo 2.0 reagent
was added to the wells and luminescence was measured
10min afterwards, using the Spark multimode microplate
reader (Tecan, Switzerland) and the Sparkcontrol method edi-
tor software (Tecan). In these experiments, OA-EVs and H-
EVs were from 3 and 6 MSC donors, respectively.
2.7. Three-Dimensional (3D) Pellet Coculture of MSC-EVs
and OA Chondrocytes. To characterize whether MSC-EVs
(both OA- and H-EVs) have an effect on chondrocytes’
expression of genes implicated in the extracellular matrix
(ECM) metabolism, EVs from 6 × 106 OA or control MSCs
were added to 6 × 105 chondrocytes resuspended in EV-
depleted DMEM:F12/10%FBS media (MSC-EVs to chon-
drocytes ratio 10 : 1). Afterwards, chondrocytes were sepa-
rated into 3 different tubes and centrifuged at 450 × g for
10min to create 3D pellets, for each treatment. In addition,
2 × 105 chondrocytes were pelleted in EV-depleted
DMEM:F12/10%FBS media without MSC EVs and used as
negative controls (No EVs). After 2 and 7 days, EV-
depleted media was half-changed and cell pellets were taken
for RNA isolation. In these experiments, OA-EVs and H-
EVs were from 2 different donors each, and the chondrocyte
cultures (n = 3) were not donor-matched to OA-MSCs.
Longer-term effect of OA and healthy MSC-EVs on
chondrocyte gene expression in the pellet culture was tested
using a single-donor chondrocyte culture and MSC to chon-
drocyte ratio of 4 : 1, with half-change medium every 3-4
days.
2.8. RNA Isolation from OA and Healthy MSC-EVs, Parental
MSCs, and MSC-EV-Treated Chondrocytes. For isolation of
RNA from EVs (60μl of the EVs suspension in PBS), total
Exosome RNA and Protein Isolation kit (ThermoFisher Sci-
entific) were used following the manufacturer’s instructions.
The RNA concentration from EVs was assessed using the
Bioanalyzer 2100 and the RNA 6000 pico kit (Agilent Tech-
nologies, USA).
RNA from parental MSCs (from which EVs were pro-
duced from) and from chondrocyte pellets was obtained
using the miRNeasy Mini kit (Qiagen) following the manu-
facturer’s instructions. The RNA was quantified using the
Nanodrop spectrophotometer (ThermoFisher Scientific).
2.9. miRNA Profiling from OA and Healthy MSC-EVs.
miRNA profiling was carried out using the nCounter®
Human v3.0 miRNA Expression Assay Kit (NanoString
Technologies), based on miRBase v21, from total RNA
obtained from OA-EVs and H-EVs as well as parental MSCs
(the MSCs from which the respective EVs were obtained
from). The code set incorporated 799 mature microRNAs
and included 6 positive controls, 8 negative controls, 6 liga-
tion controls, 5 mRNA housekeeping controls (ACTB, B2M,
GAPDH, RPL19 and RPLP0) and 5 spike-in controls. miRtag
ligation, miRNA CodeSet Hybridization and post-
hybridization were performed following the manufacturer’s
instructions. The resulting miRNA expression profiles were
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analyzed using the nSolver software V4 (NanoString Tech-
nologies). Samples were normalized to the geometric mean
of the Top100 miRNAs taking into account background
thresholding and positive control normalization (geometric
mean). Fold change (FC) expression differences between
groups were calculated using nSolver v2.5 (NanoString
Technologies) ratio data, based on normalized count data.
Further analysis was performed using a pipeline designed
by Newcastle University, Haematological Sciences Depart-
ment. This integrated a number of R (R project) statistical
packages in the R programming language; p values between
two groups were generated using a two-tailed t-test. Analysis
on miRNA targets was performed using mirWalk [44], mir-
Path from DIANA Tools [45], Reactome [46] and miRDIP
[47], utilizing default parameters for Human or Homo
sapiens.
2.10. Quantitative Real Time PCR. Gene expression was
assessed in 2, 7, and 21 day-cultured OA and healthy
MSC-EV-treated pellets and control chondrocyte pellets.
Total RNA was isolated and reverse transcribed with the
High-Capacity cDNA Reverse Transcription kit (Applied
Biosystems). qRT-PCR was performed using the Taqman
assays (ThermoFisher Scientific; Table 1) and Fast Advanced
Master Mix (Applied Biosystems, ThermoFisher Scientific)
in a QuantStudio 3 Real-Time PCR system (Applied Biosys-
tems). Genes for the analysis were selected based on the lit-
erature evidence of their involvement in the chondrogenesis
and chondrocyte catabolic and anabolic activity [12, 48] and
are shown in Table 1.
3. Results
3.1. EV Characterization. EVs isolated from OA-MSCs
(n = 5) showed similar basic characteristics (Figure 1) than
previously shown for control healthy MSCs [41]. Expression
of different markers of small EVs [25] in OA-EV prepara-
tions was first tested using flow cytometry (Figure 1(a)).
CD63 (95:9% ± 7:4%) and CD81 (90:1% ± 13:0%) were the
highest expressed markers followed by CD9 (66:1% ± 23:8%)
indicating presence of small EVs (Figure 1(a)). The morphol-
ogy of OA-EVs observed using TEM was a typical cup-shape
(Figure 1(b)). The concentration of particles and the size of
the EVs was measured using NTA (Figure 1(c), Table 2).
The mode of the OA-EV size ranged between 107.9-
169.8 nm (Table 2) not significantly different to H-EVs
(81.3-132.9), and consistent with the modal size previously
reported for control H-EVs [41]. The mean concentration of
particles per ml in OA-EV preparations was 1:38 × 1011 ±
2:07 × 1010 and is similar to that of the H-EVs
(1:12 × 1011 ± 8:50 × 109) (Table 2). As cell number was
counted after OA and healthy MSC-EV media collection, no
differences (p > 0:05) were found in the mean number of par-
ticles obtained per cell from either OA or control MSCs: 634
± 176 and 709 ± 447, respectively. Neither difference was
observed when comparing mean EV size between healthy
and OA-MSC-EVs (p > 0:05): 112:7 ± 23:50nm and 138:2 ±
25:68nm, respectively, but OA-EVs seemed less variable than
H-EVs (Figure 1(c)). These data indicated that OA-MSCs had
a similar capacity to produce EVs with a comparable modal
size and particle concentration as control healthy MSCs.
3.2. The Effects of OA and Healthy MSC-EVs on Chondrocyte
Viability. An ATP-based viability assessment was performed
following coculture of OA chondrocytes with OA- or H-
EVs. When comparing untreated chondrocytes with those
treated with control H-EVs, an average 6.27% increase in
chondrocyte viability was found (p value = 0.020)
(Figure 2(a)). OA-EV treated chondrocytes also showed
increased viability compared to untreated chondrocytes
(average 5.92%, p value= 0.042) (Figure 2(b)). However,
the difference in the percentage increase of viability
between OA and H-EVs failed to reach statistical signifi-
cance (p value = 0.768) (Figure 2(c)).
3.3. The Effects of OA and Healthy MSC-EVs on Chondrocyte
Gene Expression. In these experiments, pellet culture of
chondrocytes and EVs was used to facilitate EV uptake by
chondrocytes, as reported previously [49]. The media used
in these experiments did not contain any chondrogenic
inducers because the latter could ‘mask’ potentially smaller
effects by EVs. To confirm that pellet culture environment
was sufficient to induce chondrogenic gene up-regulation
in chondrocytes, and to investigate how it affected the
expression of the selected catabolic and anabolic genes, a
time-course experiment in untreated pelleted chondrocytes
from 4 donors was performed (Figure 3(a)).
As expected, gradual increases in chondrogenesis
markers SOX9, COL2 and ACAN, as well as COL1, were seen
from day 2 onwards confirming that pellet culture in the
Table 1: Taqman assays used for qPCR on MSC-EV (both OA- and H-EVs) treated chondrocytes.
Gene name Gene symbol Probe/assay ID
SRY (sex determining region Y)-box 9 SOX9 Hs00165814_m1
Collagen type II alpha 1 chain COL2A1 Hs00264051_m1
Aggrecan ACAN Hs04982230_s1
Collagen type I alpha 2 chain COL1 Hs01028969_m1
Matrix metallopeptidase 13 MMP13 Hs00942586_m1
A disintegrin and metalloproteinase with thrombospondin motifs 4 ADAMTS4 Hs00192708_m1
A disintegrin and metalloproteinase with thrombospondin motifs 5 ADAMTS5 Hs01095518_m1
Glyceraldehyde 3-phosphate dehydrogenase GAPDH Hs02758991_g1


































































Figure 1: OA-MSC-EV characterization. (a) Flow cytometry of CD63, CD9, and CD81 surface markers (representative OA-EV sample).
Red and blue histograms illustrate isotype controls and stained samples, respectively. (b) Transmission Electron Microscopy showing the
cup-shape morphology of EVs (representative OA-EV sample, scale bar 200 nm). (c) Scatter plot showing size and number of
particles/cell analysis of OA and control H-EVs, assessed by nanoparticle tracking analysis.
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absence of chondrogenic inducers was sufficient to monitor
the effect of EVs on chondrogenic gene up-regulation. The
up-regulation of other transcripts (MMP13, ADAMTS4
and ADAMTS5) did not similarly continue beyond day 7
(Figure 3(a)).
An average 18% up-regulation of SOX9 transcript com-
pared to untreated chondrocytes was observed in coculture
with H-EVs and the effect was smaller (average 4% increase)
in coculture with OA-EVs however the differences failed to
reach statistical significance (Figure 3(b)). A trend for
lower-level upregulation of SOX9 by OA-EVs compared to
H-EVs, as well as of transcripts for mature cartilage ECM
proteins COL2 and ACAN was evident following longer-
term culture (Figure 3(c)). Higher COL2/COL1 ratio indicat-
ing chondrogenic lineage commitment displayed the same
trend, unlike the expression of cartilage catabolic molecules
where no specific trends were found (both short- and long-
term) (Figure 3(c)).
3.4. miRNA Profiling. Albeit not being statistically signifi-
cant, average of 1.5-fold differences in chondrocytes’ chon-
drogenesis gene expression (SOX9, COL2 and ACAN
expression at 21 days), indicated potential differences in
microRNA cargo between H-EVs and OA-EVs. microRNA
expression profiling was next performed on H-EVs and
OA-EVs (n = 4 cultures each) using NanoString technology
(n = 799 microRNA). Expression of 590 mature microRNAs
was detected across all samples after correcting for back-
ground (Supplementary Data 1). Healthy and OA-EVs
showed distinct microRNA expression profiles, as demon-
strated using unsupervised hierarchical clustering analysis
(Figure 4). There were 75 miRNAs that were significantly
Table 2: Summary of EV characteristics isolated from OA and healthy MSCs: particle size, concentration of particles, and the number of
cells from which EVs were obtained.
Sample
Particle size Concentration of particles
Particles/cell∗
Mean (nm) SD (nm) Mode (nm) Particles/ml∗ Particles/frame∗
OA-EV1 161.6 69.3 169.8 1:19 × 1011 ± 1:64 × 1010 12:1 ± 1:7 692 ± 95
OA-EV2 172.2 75.0 121.1 1:30 × 1011 ± 1:69 × 1010 13:2 ± 1:7 531 ± 69
OA-EV3 177.2 87.4 158.4 1:15 × 1011 ± 1:07 × 1010 11:7 ± 1:1 622 ± 58
OA-EV4 160.0 71.6 133.7 1:35 × 1011 ± 3:20 × 1010 13:7 ± 3:2 433 ± 103
OA-EV5 172.0 71.1 107.9 1:92 × 1011 ± 2:75 × 1010 29:2 ± 4:2 897 ± 128
H-EV1 184.1 89.4 132.9 2:36 × 1011 ± 2:53 × 1010 77:4 ± 8:1 3670 ± 393
H-EV2 152.3 67.4 110.2 7:43 × 1010 ± 4:76 × 109 61:7 ± 4:0 1265 ± 81
H-EV3 125.2 52.9 100.7 5:58 × 1010 ± 2:9 × 109 27:2 ± 1:5 1240 ± 64
H-EV4 154.8 63.6 107.9 9:41 × 1010 ± 1:11 × 1010 46:7 ± 5:7 752 ± 88
H-EV5 129.6 55.3 81.3 5:76 × 1010 ± 3:32 × 109 21:6 ± 1:4 694 ± 40
H-EV6 152.1 79.7 98.4 1:53 × 1011 ± 3:59 × 109 77:7 ± 2:2 3035 ± 71

















































Figure 2: The effect of EVs on chondrocyte viability in CellTitter-Glo assay. (a) Viability of chondrocytes measured in luminescence units
when treated with H-EVs (+), compared with untreated OA chondrocytes (-). (b) Viability of chondrocytes when treated with EVs from
OA-MSCs (+), compared with untreated chondrocytes (-). (c) Percentage increase in viability above the untreated controls between H-
EVs and OA-EVs. Horizontal bars show medians, and whiskers represent min to max. ∗p value < 0.05. Paired t-test analysis.
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Figure 3: Gene expression of characteristic cartilage catabolic and anabolic genes measured in (a) untreated chondrocytes (no EVs) cultured
for 2, 7, and 21 days. Horizontal bars show medians, and whiskers represent interquartile range. (b) SOX9 expression in untreated and H-EV
or OA-EV treated chondrocytes after 2 and 7 days. Symbols represent individual donor-derived chondrocyte cultures. (c) Chondrogenic
gene expression in untreated (no EVs) and treated (H-EVs and OA-EVs) chondrocytes after 2, 7, and 21 days.
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differentially expressed between H-EVs and OA-EVs, of
which 48 retained significance after FDR correction. A total
of 47 were upregulated in healthy EVs and 1 in OA-EVs
(fold change (FC) range = −12:3 − 26:67, p value range =
0.002-0.037) (Figure 4).
The 48 DE-expressed microRNAs were predicted to tar-
get KEGG pathways [50] using mirPath [45], with key impli-
cations in chondrogenesis or stem cells, including
extracellular matrix interaction (56 genes, 36 microRNAs,
p < 0:001), N-glycan biosynthesis (30 genes, 29 microRNA,
p < 0:001), focal adhesion (133 genes, 43 microRNAs, p <
0:001) and signalling pathways regulating pluripotency of
stem cells (94 genes, 45 microRNAs, p < 0:001). Predicted
gene targets identified with ‘very high’ score class (top 1%)
via the microRNA Data Integration Portal (mirDIP) were
filtered for duplicates, resulting in 10,755 unique gene tar-
gets. Reactome pathways implicated by the target genes
included cell-cell communication (95/133 genes), transcrip-
tional regulation of pluripotent stem cells (38/45 genes),
extracellular matrix organisation (207/329 genes), transport
of small molecules (483/967 genes), and vesicle-mediated
transport (510/824 genes). miRWalk also predicted target
map to signalling pathways “regulating pluripotency of stem
cells” pathway.
In addition to microRNAs that were significantly differ-
entially expressed between OA-EVs and H-EVs, we also
assessed the top 20 most highly expressed microRNAs in
each population, as well as those that were commonly highly
expressed in both OA and H-EVs. 17 microRNA were
expressed at a high level in both populations, while miR-
6721-5p, miR-579-3p and miR-199a-5p were uniquely
highly expressed in OA-MSC-EVs, and miR-145-5p, miR-
126-3p and miR-15b-5p were uniquely highly expressed in
control healthy MSC-EVs (Table 3).
The top 5 most highly expressed microRNAs in each
population comprised over 50% of all microRNA reads
(OA − EVs = 50:2%, H − EVs = 62:0%) (Figure 5), of which
miR-4454/-7975, miR-125b-5p, and miR-21-5p were com-
monly highly expressed.
When we compared miRNAs in OA-EVs with their
parental MSCs (Supplementary Data 2), we found that they



























































































Figure 4: OA-EV and H-EV miRNA expression profiling using NanoString technology. Heatmap showing unsupervised hierarchical
clustering of significantly differentially expressed microRNAs (p < 0:05, n = 48), based on normalized digital expression counts in OA-
EVs vs. H-EVs. Each column represents an individual sample. Relative expression changes are indicated by the colour key (red: high;
blue: low). OA-EVs are depicted by grey shading, while H-EVs are depicted by black shading.
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were significantly differentially expressed between OA-EVs
and parental OA-MSCs, of which 124 retained significance
after FDR correction (Figure 6). A total of 120 were
upregulated in healthy EVs and 4 in OA-EVs (fold change
(FC) range = −75:95 − 68:62, p value range≤ 0.001-0.049)
(Figure 4).
For KEGG pathway analysis [50], 100 miRNA with
higher FC out of the 124 DE expressed microRNAs were
analyzed using mirPath [45]. The same key implications in
chondrogenesis or stem cells were found as above, with the
exception of pathways regulating pluripotency of stem cells:
extracellular matrix receptor interaction (71 genes, 77
microRNAs, p < 0:001), N-glycan biosynthesis (44 genes,
58 microRNA, p < 0:001) and focal adhesion (177 genes,
82 microRNAs, p < 0:001). Other pathways observed were
proteoglycans in cancer (180 genes, 80 microRNAs, p <
0:001), fatty acid metabolism (42 genes, 66 mircroRNAs,
p < 0:001) or cell cycle (111 genes, 77 microRNAs, p <
0:001). Predicted gene targets with ‘very high’ score class
(top 1%) via the microRNA Data Integration Portal (mir-
DIP) were identified, resulting in 100,714 unique gene tar-
gets. Reactome pathways implicated by the target genes
included MECP2 regulated neuronal receptors and channels
(32/32), transcription factor forkhead box O (FOXO)-medi-
ated transcription (85/110 genes), TP53 regulated transcrip-
tion of genes involved in G1 cell cycle arrest (20/20),
transcriptional regulation by RUNX family transcription
factor 3 (RUNX3) (87/118 genes), extracellular matrix orga-
nization (249/329 genes), programmed cell death (170/238
genes), and vesicle-mediated transport (552/824 genes).
miRWalk predicted target map to signalling pathways
related to cartilage and osteoarthritis as “glycolysis_gluco-
neogenesis”, “fatty acid metabolism”, “glycosaminoglycan
biosynthesis”, “autopaghy”, “FOXO signaling pathway”,
“calcium signaling pathway”, “osteoclast differentiation”,
and other pathways like “endocytosis” or “cell cycle”.
Assessing the top 20 most highly expressed microRNAs,
14 microRNAs were expressed at a high level in both paren-
tal OA-MSCs and their EVs, while 6 miRNAs were uniquely
highly expressed in OA-MSC-EVs and other 6 were
uniquely highly expressed in parental MSCs (Table 4).
4. Discussion
Previous studies on EVs in OA have almost exclusively
focused on the synovial fluid (SF) EVs, which mediate
the cross-talk between the damaged cartilage and the
inflamed synovium [51, 52] and have shown their consid-
erable influence on chondrocyte catabolism, senescence,
and death [53–57]. In contrast, the cross-talk between sub-
chondral bone (SB) cells and chondrocytes in OA is com-
paratively less explored, despite the fact that SB pathology
is implicated in all stages of OA progression [13, 58, 59].
Furthermore, in previous studies of SF-resident EVs, their
tissues of origin, as well as the cells of origin, remained
unknown. In contrast, our study is uniquely focused on
the cross-talk between cartilage and SB in OA and investi-
gated EV production from a specific type of SB cells, SB
MSCs, which are directly implicated in SB OA pathology
and cartilage destruction “from below” [60–62]. Although
SB MSCs from healthy amputees would be a better control
than the MSCs from bone marrow used in this work,
these samples are difficult to access while MSCs from
amputated knees from diabetics could carry underlying
negative effects such as described previously [63–65].
In this work, when comparing EV size and yields (par-
ticle/cell) released from OA and control healthy MSCs, no
differences were found, similar to results previously
described for healthy and OA-EVs from SF [55, 57].
Previous works on SF-EVs have presented slightly lower
EV sizes [53–55], which could be explained by different
methods used for EV isolation in these studies: using
ultracentrifugation combined with precipitation [54, 55]
or using immunoaffinity [53]. EVs obtained from ultracen-
trifugation alone, as was in our study, are known to be less
purified due to the overlap in sizes between EVs and
microvesicles [25], however ultracentrifugation is less
harmful for EVs [66].
One of the principal aims of this study was to identify
specific sets of miRNAs in the OA-EVs derived from SB-
MSCs. Depending on the cell of origin, EVs (including exo-
somes) can contain many constituents of a cell including
DNA, RNA, lipids, metabolites, and cytosolic and cell- sur-
face proteins [67]. We have identified several miRNAs that
in our experimental conditions were packaged into their
EVs and may be characteristic of OA-EVs from these cells.














































Figure 5: OA-EV and H-EV miRNA profiling analysis. Diagrams showing the percentages of reads from the top 5 most highly expressed

















































Figure 6: miRNA profiling of OA-EVs and their parental MSCs using NanoString technology. Heatmap showing unsupervised hierarchical
clustering of significantly differentially expressed microRNAs (p < 0:05, n = 124), based on normalized digital expression counts in OA-
MSC-EVs vs. OA-MSCs. Each column represents an individual sample. Relative expression changes are indicated by the colour key (red:
high; blue: low). OA-MSC-EVs are depicted by grey shading, while MSC are depicted by black shading.
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Many previous studies compared miRNA expression in
MSC-EVs and their parental MSCs [68–72], but these stud-
ies were all focused on healthy MSCs. Our study has identi-
fied 14 miRNAs that were highly expressed in both OA-
MSC-EVs and their parental SB MSCs. These included
miR-125b, which has been previously shown to regulate
the expression of matrix-degrading enzymes in human
chondrocytes [73–75] as well as regulate MSC osteogenesis
[76], and miR-199a involved in repression of chondrogene-
sis [77], regulation of chondrocyte ageing and cartilage
metabolism [78], and highly expressed in OA SF EVs [57].
Previous studies including ours [18, 61, 79] have described
gene expression profiles of OA SB MSCs as predisposed
towards bone formation and cartilage extracellular matrix
regulation. The current study complements these findings
by showing that highly expressed miRNA in these MSCs,
including those packaged in their EVs, may be regulating
cartilage homeostasis in OA. Although further functional
analysis would be necessary to confirm that these miRNAs
contained in the EVs may produce this chondrogenic effect.
Furthermore, the present study has identified four miR-
NAs that are higher-expressed in OA-MSC-EVs compared
to parental MSCs and may be involved in regulating the via-
bility and the metabolic status of OA chondrocytes. Of a
particular interest are miR-142-3p previously shown to be
selectively packaged into EVs [80] and miR-223-3p that
have been both shown to inhibit cell apoptosis and inflam-
mation in OA chondrocytes [81, 82], as well as miR-630 that
has been earlier documented to regulate chondrogenic line-
age commitment [83]. In our previous work we have used
qPCR and validated the enrichment of miR-142-3p and
miR-223-3p in H-EVs coming from MSCs [41]. The role
of miR-630 and other miRNAs has not yet been explored
in OA and is awaiting further validation.
Pathway analysis has indicated that OA-EVs and/or OA-
MSCs expresses miRNAs implicated in chondrogenesis,
stem cells, or other pathways related to cartilage and OA.
Interestingly, “fatty acid metabolism” points out to the
already known role of fatty acids in OA [84]. Also, FOXO
transcription factors have been described as chondroprotec-
tors and regulating autophagy and inflammation [85]. Alto-
gether, these data suggest that despite their altered gene
expression and predisposition to osteogenesis in OA, SB
MSCs produce miRNAs and release EVs that contain miR-
NAs involved in positive regulation of chondrocyte viability
and differentiation.
MSC-EVs from various human tissues including bone
marrow (BM) and adipose tissue are beginning to be used
as a therapy for OA [52, 86]. In this context, it was interest-
ing to compare the miRNA cargo of OA-EVs with H-EVs
obtained from BM aspirates from healthy individuals.
Amongst top highly expressed miRNAs, 17 were shared in
both types of EVs (Table 3), 13 of which were also abundant
in OA-MSCs (Table 4). Common abundant miRNAs
included miR-16-5p previously used as an endogenous refer-
ence gene for the normalization of urinary exosomal miRNA
expression [87], and some let family members previously
described amongst the top 10 most abundant miRNAs in
humans’ samples [88, 89]. Common miRNAs between
OA-EVs and H-EVs that were not present in OA-MSCs
included previously noted miR-142-3p and miR-630 [86]
that have been described as “cartilage-protective.” Also
miR-29a-3p was described as protective for cartilage [86].
Healthy EVs higher-expressed miR-145-5p (uniquely highly
expressed in H-EVs compared to OA-EVs) described as
having a dual role in OA [90], while OA-EVs higher-
expressed hsa-miR-199a-5p involved in chondrogenesis
regulation and bone formation [91], as well as highly
expressed in OA SF EVs [57] and in plasma of early OA
patients [92]. Our in vitro data have revealed that both
H-EVs and OA-EVs marginally but significantly improved
the viability of OA chondrocytes, with no difference to each
other, which could be a result of consorted activity of mul-
tiple miRNAs.
Recent in vitro studies on MSC-EVs in OA have used
inflammatory stimulation of chondrocytes before cocultur-
ing with H-EVs [93–96], and they obtained a reduction in
the expression of chondrocyte inflammatory markers. It
could be possible that this stimulation made the EV-
effect on chondrocytes stronger than observed in our
study. In our study, we aimed to reflect more closely the
in vivo conditions of chondrocytes based on our previous
findings that OA chondrocytes grown in the same


































conditions already present the signs of inflammation, evi-
dent by high-level expression of matrix-degrading enzymes
and pro-inflammatory cytokines [18].
Even though our data on MSC-EV (both OA- and H-
EVs) effects on chondrocyte gene expression are limited,
they point towards a worse induction of chondrogenic gene
expression by OA-EVs compared to H-EVs. The lack of sta-
tistical significance could be explained by donor-to-donor
variation in both chondrocytes and EVs preparations that
we have used. To minimise donor effects and generate larger
EV batches for use in multiple experiments, future studies
could utilise EVs [54] or chondrocytes [49] which are pooled
from several donors.
Smaller than expected effects of EVs on chondrocyte
gene expression could be also explained by the 3D assay con-
ditions we used. Mortati and colleagues [49] added MSC-
EVs to 4-week cultured-chondrocyte pellets and showed that
EVs could diffuse into the matrix. Differently from their
study, we mixed the EVs with the chondrocytes before the
3D pellet formation as investigated their effect at different
time points of chondrogenesis. Also, no chondrogenic
inducers such as TGFβ1 [49] were added to the media in
our study because these strong inducers could “mask” or
conflict with potentially smaller effects from MSC-EVs. In
support of our assay design, previous studies have docu-
mented the presence of TGFβ1 in MSC-EVs [97], which
could explain long-term, enhanced chondrogenic gene
expression with the addition of H-EVs in our experiments.
While some studies report on MSC-EV enhancement of
chondrocyte collagen II expression in 2D formats [94], 3D
pellets [48], cells encapsulated in cartilage-mimicking
hydrogels [49] are likely to provide conditions more repre-
sentative to EV traffic in vivo. Specific to OA osteochondral
pathology, such constructs should take into the account
intercellular distances between SB MSCs and chondrocytes,
which can be established from histological studies [6, 18],
as well as a known heterogeneity of chondrocyte subpopula-
tions in OA [98, 99], which is difficult to re-capitulate in
in vitro systems.
In summary, OA-EVs were capable to enhance the via-
bility of OA chondrocytes; also, the expression of chondro-
genic genes was enhanced in the chondrocytes by the EVs
from OA-MSCs. However, both effects were less evident
than the ones shown for H-EVs. This variation could be par-
tially explained by the differential expression of miRNAs
found in the cargo of H-EVs and OA-EVs.
5. Conclusions
The present study reports on the production, characteriza-
tion and miRNA profile of EVs from SB MSCs in OA. For
the first time, it shows that SB MSCs in OA are capable of
producing EVs that support chondrocyte viability and chon-
drogenic gene expression, although future studies would be
needed to confirm it using functional assays for chondrogen-
esis. This supports the notion that modulation of SB MSCs
represents a valid strategy for endogenous cartilage regener-
ation in OA. This may be achieved via enhancement of their
trophic activity and EV production in addition to triggering
their chondrogenic differentiation, thus representing a new
potential tool for cartilage regeneration.
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Supplementary Materials
Supplementary 1. Supplementary Figure 1: characterization
of MSCs from subchondral bone (SB) of OA patients (OA-
MSCs). (A) Trilineage differentiation of OA-MSCs following
induction and staining with Oil Red O (day 21), Alkaline
phosphatase (day 14) and Toluidine Blue (day 21), for adi-
pogenesis, osteogenesis and chondrogenesis, respectively.
(B) Phenotypic profile of OA-MSCs showing the % expres-
sion of CD73, CD90, CD105, hematopoietic-lineage markers
(CD45, CD34, CD19, CD14) and HLA-DR measured by
flow cytometry. Original magnification x200 for adipo- and
osteo- genesis and x40 for chondrogenesis.
Supplementary 2. Supplementary Figure 2: characterization
of MSCs from healthy controls (H-MSCs). (A) Trilineage
differentiation of H-MSCs following induction and staining
with Oil Red O (day 21), Alkaline phosphatase/Von Kossa
(day 14) and Alcian Blue (day 21) for adipogenesis,
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osteogenesis and chondrogenesis, respectively. (B) Pheno-
typic profile of H-MSCs showing the % expression of
CD73, CD90, CD105, hematopoietic-lineage markers
(CD45, CD34, CD19, CD14) and HLA-DR measured by
flow cytometry. Scale bar 200μm for adipo- and osteo- gen-
esis and 500μm for chondrogenesis.
Supplementary 3. Supplementary Data 1: analysis of miR-
NAs in OA-EVs compared with H-EVs, showing the differ-
ential expression, with and without FDR correction, fold
change (FC) and p value.
Supplementary 4. Supplementary Data 2: analysis of miR-
NAs in OA-EVs compared with their parental MSCs,
showing the differential expression, with and without FDR
correction, fold change (FC) and p value.
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